Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma

Bone Marrow Transplantation volume 46, pages 923–928 (2011)Cite this article

Subjects

Abstract

The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate the safety and efficacy of the MCVAC regimen (consisting of ranimustine (MCNU), cytarabine, etoposide and CY) followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with high-risk or relapsed DLBCL. A total of 40 patients with DLBCL who received the MCVAC regimen followed by autologous PBSCT were retrospectively evaluated. Median follow-up duration of the surviving patients was 51.2 months (range, 5.4–151.2 months). At 5-year OS and PFS were 73.7% (95% confidence interval (CI), 58.6–88.8) and 62.5% (95% CI, 46.8–78.2), respectively. Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML. In conclusion, the MCVAC regimen would be an effective and tolerable conditioning regimen without TBI for autologous PBSCT for high-risk or relapsed DLBCL. However, late-onset pulmonary toxicity and MDS/AML should be monitored.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033.

    Article  CAS  Google Scholar 

  2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126.

    Article  CAS  Google Scholar 

  3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391.

    Article  CAS  Google Scholar 

  4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006.

    Article  CAS  Google Scholar 

  5. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122.

    CAS  PubMed  Google Scholar 

  6. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210–218.

    Article  CAS  Google Scholar 

  7. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176.

    Article  CAS  Google Scholar 

  8. Caballero MD, Amigo ML, Hernandez JM, Vazquez L, del Canizo C, Gonzalez M et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann Hematol 1997; 74: 79–82.

    Article  CAS  Google Scholar 

  9. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633–3642.

    Article  CAS  Google Scholar 

  10. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615–1623.

    Article  CAS  Google Scholar 

  11. Salles G, Shipp MA, Coiffier B . Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol 1994; 31: 46–69.

    CAS  PubMed  Google Scholar 

  12. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  13. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734–1741.

    Article  CAS  Google Scholar 

  14. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  Google Scholar 

  15. Meehan KR, Pritchard RS, Leichter JW, Littenberg B, Welch HG . Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Am J Hematol 1995; 50: 116–123.

    Article  CAS  Google Scholar 

  16. Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J, Lahuerta JJ et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27: 405–412.

    Article  CAS  Google Scholar 

  17. Takaue Y, Watanabe T, Hoshi Y, Abe T, Matsunaga K, Saito S et al. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features. Cancer 1991; 67: 1830–1837.

    Article  CAS  Google Scholar 

  18. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

    Article  Google Scholar 

  19. Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra J, Marin J et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140–151.

    Article  CAS  Google Scholar 

  20. Martin A, Caballero MD, Perez-Simon JA, Lopez-Holgado N, Mateos MV, Canizo MC et al. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. Bone Marrow Transplant 2004; 34: 675–682.

    Article  CAS  Google Scholar 

  21. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008; 87: 43–48.

    Article  CAS  Google Scholar 

  22. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015–2023.

    Article  CAS  Google Scholar 

  23. Howe R, Micallef IN, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 32: 317–324.

    Article  CAS  Google Scholar 

  24. Patti C, Majolino I, Scime R, Indovina A, Vasta S, Liberti G et al. High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. Eur J Haematol 1993; 51: 18–24.

    Article  CAS  Google Scholar 

  25. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.

    Article  CAS  Google Scholar 

  26. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens—a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48–55.

    Article  CAS  Google Scholar 

  27. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    J Kato, T Mori, K Yokoyama, Y Tsukada, T Ueda, T Shimizu & S Okamoto

  2. Novartis Pharma Program for Clinical Therapeutics of Hematologic Malignancy, Keio University School of Medicine, Tokyo, Japan

    J Kato & T Ueda

Authors
  1. J Kato
    View author publications

    Search author on:PubMed Google Scholar

  2. T Mori
    View author publications

    Search author on:PubMed Google Scholar

  3. K Yokoyama
    View author publications

    Search author on:PubMed Google Scholar

  4. Y Tsukada
    View author publications

    Search author on:PubMed Google Scholar

  5. T Ueda
    View author publications

    Search author on:PubMed Google Scholar

  6. T Shimizu
    View author publications

    Search author on:PubMed Google Scholar

  7. S Okamoto
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to T Mori.

Ethics declarations

Competing interests

The authors decalre no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, J., Mori, T., Yokoyama, K. et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplant 46, 923–928 (2011). https://doi.org/10.1038/bmt.2010.243

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2010.243

Keywords

This article is cited by

Search

Advanced search

Quick links